Expression of cysteinyl leukotriene receptor-1 in pancreatic cancer tissue and its clinical significance

Meng Yan; Zhu Ying; Zhang YaQing; Zou LingYun; Zhang QiuNan

doi:10.3969/j.issn.1001-5256.2017.01.029

Issue 1

Jan. 2017

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2017 > 33(1): 133-136

PDF( 1476 KB)

Expression of cysteinyl leukotriene receptor-1 in pancreatic cancer tissue and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2017.01.029

Emergency Department, Longwan Branch of Central Hospital of Huludao, Huludao, Liaoning 125001, China

Published Date: 2017-01-20

Abstract

Abstract

Objective To investigate the expression of cysteinyl leukotriene receptor- 1( Cys LTR- 1) in pancreatic cancer tissue and its association with clinical features and prognosis. Methods A total of 42 patients with pathologically confirmed pancreatic cancer who were admitted to Central Hospital of Huludao from January to October,2015 were enrolled,and cancer and adjacent tissues were collected. Real-time PCR was used to measure the relative mRNA expression of Cys LTR- 1 in these tissues,and the patients were followed up for 1 year.The t- test was used for comparison of continuous data between groups; an analysis of variance was used for comparison between multiple groups,and the least significant difference t- test was used for comparison between any two groups. The multivariate logistic regression analysis was used to determine influential factors for the prognosis of patients with pancreatic cancer. Results The cancer tissues had significantly higher relative mRNA expression of Cys LTR- 1 than adjacent tissues( 0. 037 1 ± 0. 020 5 vs 0. 016 8 ± 0. 011 4,t = 6. 58,P<0. 001). The relative mRNA expression of Cys LTR- 1 was associated with TNM stage( t = 2. 731,P = 0. 009),degree of tumor differentiation( F = 10. 537,P < 0. 001),and lymph node metastasis( t = 3. 408,P = 0. 002). During the 1- year follow- up,17 patients died and25 survived; the patients who died had significantly higher relative mRNA expression of Cys LTR- 1 than those who survived( 0. 045 6 ±0. 021 7 vs 0. 031 3 ± 0. 019 8,t = 2. 21,P = 0. 03). The logistic regression analysis showed that TNM stage( OR = 6. 92,95% CI: 1. 30-36. 82,P = 0. 02),degree of tumor differentiation( OR = 5. 71,95% CI: 1. 44- 22. 62,P = 0. 01),and lymph node metastasis( OR =9. 62,95% CI: 2. 23- 41. 46,P < 0. 001) were prognostic factors for pancreatic cancer. After adjustment for age,sex,TNM stage,degree of tumor differentiation,tumor location,and lymph node metastasis,the mRNA expression of Cys LTR- 1 was still a prognostic factor for patients with pancreatic cancer( OR = 1. 11,95% CI: 1. 07- 1. 15,P = 0. 03). Conclusion Cys LTR- 1 is involved in the development and progression of pancreatic cancer and can be used as a new molecular marker for prognostic evaluation in patients with pancreatic cancer.
- pancreatic neoplasms,
- receptors,
- leukotriene

FullText(HTML)

References(13)

References

[1]GBD 2013 Mortality and Causes of Death Collaborators.Global,regional,and national age-sex specific all-cause and cause-specific mortality for 240 causes of death,1990-2013:a systematic analysis for the Global Burden of Disease Study 2013[J].Lancet,2015,385(9963):117-171.

[2]CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.

[3]CONROY T,BACHET JB,AYAV A,et al.Current standards and new innovative approaches for treatment of pancreatic cancer[J].Eur J Cancer,2016,57:10-22.

[4]ZAMBIRINIS CP,PUSHALKAR S,SAXENA D,et al.Pancreatic cancer,inflammation,and microbiome[J].Cancer J,2014,20(3):195-202.

[5]PU J,LI X,ZHU J,et al.Expression and roles of poly(ADP-ribose)polymerase-1 and caspase-3 in pancreatic cancer and adjacent tissues[J].J Clin Hepatol,2016,32(2):337-341.(in Chinese)蒲竞,李汛,朱骏,等.PARP-1和caspase-3在胰腺癌及癌旁组织中的表达及意义[J].临床肝胆病杂志,2016,32(2):337-341.

[6]SAVARI S,VINNAKOTA K,ZHANG Y,et al.Cysteinyl leukotrienes and their receptors:bridging inflammation and colorectal cancer[J].World J Gastroenterol,2014,20(4):968-977.

[7]JIANG KR,HU H,MIAO Y.Value of artery resection in pancreatic cancer surgery[J].J Clin Hepatol,2016,32(5):826-829.(in Chinese)蒋奎荣,胡浩,苗毅.联合动脉切除在胰腺癌手术中的价值[J].临床肝胆病杂志,2016,32(5):826-829.

[8]YANG YM.Highlights and diffculties in surgical treatment for pancreatic cacinoma[J].Chin J Dig surg,2015,14(8):612-614.(in Chinese)杨尹默.胰腺癌外科治疗的热点与难点[J].中华消化外科杂志,2015,14(8):612-614.

[9]HENNIG R,DING XZ,TONG WG,et al.5-Lipoxygenase and leukotriene B(4)receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue[J].Am J Pathol,2002,161(2):421-428.

[10]WANG X,LIU W,HAN YW,et al.Significance of cysteinyl leukotriene receptor in breast cancer[J].Chin J Clin Oncol,2012,39(20):1522-1526.(in Chinese)王欣,刘伟,韩芸蔚,等.半胱氨酰白三烯受体在乳腺癌组织中的表达及意义[J].中国肿瘤临床,2012,39(20):1522-1526.

[11]ZHANG SQ,TANG CB,CHEN WH.Expression of Cys LT1R in colorectal carcinoma tissues and its clinical significance[J].J Shanxi Med Univ,2014,45(3):177-179.(in Chinese)张世强,唐采白,陈卫花.半胱氨酰白三烯受体Cys LT1R在大肠癌组织中的表达及临床意义[J].山西医科大学学报,2014,45(3):177-179.

[12]MEZHYBOVSKA M,WIKSTROM K,OHD JF,et al.The inflammatory mediator leukotriene D4 induces beta-catenin signaling and its association with antiapoptotic Bcl-2 in intestinal epithelial cells[J].J Biol Chem,2006,281(10):6776-6784.

[13]DING X,ZHU C,QIANG H,et al.Enhancing antitumor effects in pancreatic cancer cells by combined use of COX-2 and 5-LOX inhibitors[J].Biomed Pharmacother,2011,65(7):486-490.

Relative Articles

[1]	Aiping TIAN, Yongfeng YANG. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. Journal of Clinical Hepatology, 2023, 39(3): 491-497. doi: 10.3969/j.issn.1001-5256.2023.03.002
[2]	Liang XU, Ping LI, Lin CHEN, Yuqiang FU. Natural history and non-invasive diagnosis and clinical management of chronic HBV infection overlapping with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1501-1507. doi: 10.3969/j.issn.1001-5256.2021.07.003
[3]	Aiping WANG, Chunyang WEN. Thoughts on recommendations for immune-tolerant phase of chronic hepatitisB virus infection in Guidelines for the management of hepatitis B (version 3.3) released by the Japan Society of Hepatology[J]. Journal of Clinical Hepatology, 2021, 37(7): 1528-1528. doi: 10.3969/j.issn.1001-5256.2021.07.009
[4]	Li XIAO, Jianchun XIAN. Patients in the immune-tolerant phase of chronic hepatitis B can receive antiviral therapy conditionally[J]. Journal of Clinical Hepatology, 2021, 37(4): 781-782. doi: 10.3969/j.issn.1001-5256.2021.04.010
[5]	Jun JIANG, Fuzhong WU, Deyang WANG. Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent[J]. Journal of Clinical Hepatology, 2021, 37(11): 2545-2545. doi: 10.3969/j.issn.1001-5256.2021.11.010
[6]	Ling QING, Weiqiang HUANG, Xiaohe LI, Feng CHEN, Yingxia LIU. Efficacy of antiviral therapy for chronic hepatitis B with nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(9): 2075-2080. doi: 10.3969/j.issn.1001-5256.2021.09.015
[7]	Yang DING, Xiaoguang DOU. How far are we from the "Treat all" era of antiviral therapy for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(11): 2546-2547. doi: 10.3969/j.issn.1001-5256.2021.11.011
[8]	Lina JIANG, Wei Li, Jingmin ZHAO. Current status and perspectives of the clinical and basic research on concomitant chronic hepatitis B virus infection and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1489-1494. doi: 10.3969/j.issn.1001-5256.2021.07.001
[9]	Yanhua TANG, Xingyu LU, Jian SUN. Chronic hepatitis B virus infection with nonalcoholic fatty liver disease: Problems faced by antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(7): 1508-1514. doi: 10.3969/j.issn.1001-5256.2021.07.004
[10]	Li WenMi, Wang Nan, Bian Qian, Huang Qian, Li JingTao, Wei HaiLiang, Yan ShuGuang. Role of liver X receptor in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2349-2352. doi: 10.3969/j.issn.1001-5256.2020.10.041
[11]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[12]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[13]	Lu BingJie, Chen Xi, Sun MingYu. Application of lipid-regulating drugs in prevention and treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2444-2448. doi: 10.3969/j.issn.1001-5256.2017.12.043
[14]	Xie Xiao, Lu LunGen. Potential therapeies for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2439-2443. doi: 10.3969/j.issn.1001-5256.2017.12.042
[15]	Feng Gong, Niu ChunYan. Advances in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(12): 2433-2438. doi: 10.3969/j.issn.1001-5256.2017.12.041
[16]	Guo YinYan, Li Peng. A study on the role of serum Retinol Binding Protein 4 in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2012, 28(4): 279-280+301.
[17]	Qiu RongYuan, He ShengSong, Chen Feng, Pang Ran. Construction of eukaryotic expression vector of P21 mutation type by nuclear location signal and its effect on virus replication in HepG2.2.15 Cells[J]. Journal of Clinical Hepatology, 2010, 26(4): 387-391.
[18]	Chen Sheng, Lin ChaoShuang. The relationship between liver function and immune system and viral replication in patients with viral hepatitis[J]. Journal of Clinical Hepatology, 2007, 23(2): 94-95.
[19]	Yang XiaoJuan, Wu GuoRong, Lu ZhongHua, Pei Hao, Qian JinJuan. Clinical signification of detecting PreS;antigen for identifying viral replication in patients with HB without HbeAg[J]. Journal of Clinical Hepatology, 2007, 23(5): 340-341.

Supplements(0)

Cited By

Cited by

Periodical cited type(6)

1.	张明. 酒精性肝病合并乙型肝炎病毒感染病例临床分析. 中国医药指南. 2024(02): 114-116 .
2.	吴琦玮，高杨，李艳辉，沈榕. 2015—2019年北京地区乙型肝炎疾病负担及趋势预测分析. 实用预防医学. 2024(11): 1349-1352 .
3.	董丹丹，邱利，胡毅. 慢性HBV感染合并非酒精性脂肪性肝病患者血清脂联素、ROS及糖脂代谢特征. 肝脏. 2024(10): 1265-1268+1273 .
4.	毛垚耀，何惠昌，谢露，崔健娇，刘光伟. 健脾活血解毒方联合恩替卡韦对乙型病毒性肝炎合并非酒精性脂肪性肝病小鼠的干预作用及机制. 现代中西医结合杂志. 2023(08): 1047-1052 .
5.	沈从乐，李韦杰，任博，孙继云，王雅杰. 2543例不同病因慢性肝病糖脂代谢异常率分析. 标记免疫分析与临床. 2022(09): 1451-1454 .
6.	倪盟，曾雷. miRNA单核苷酸多态性与HBV感染相关疾病关系的研究进展. 吉林大学学报(医学版). 2021(06): 1588-1593 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2559) PDF downloads(445)

Expression of cysteinyl leukotriene receptor-1 in pancreatic cancer tissue and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2017.01.029